Verastem Closes $16M Series A Financing
Published On November 16, 2010 |
Verastem, Inc., a Boston, MA-based biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, which are an underlying cause of tumor recurrence and metastasis, closed a $16m Series A financing.
Founding investor, Longwood Founders Fund, was joined by Bessemer Venture Partners, Cardinal Partners, and MPM Capital.
Co-founded by Rich Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric Lander, Robert Weinberg and Christoph Westphal, the company uses its cancer stem cell screening technology to identify therapies to treat a broad range of cancers, including breast cancer.
Verastem’s scientific advisory board include Julian Adams, George Daley, Daniel Haber, Yossi Schlessinger, Phil Sharp, Roger Tung, Chris Walsh, and Eric Winer. They will advise the company as it discovers and develops new types of drugs for the treatment of cancer.